Physician profile
Jon Walheim
NPI 1801864004
$2,666.91
in general payments reported to CMS, 2019-2025
30 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $237 · 2021: $567 · 2022: $473 · 2023: $513 · 2024: $363 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $538.73 | 2021-2025 | Ubrelvy, Vraylar |
| Novo Nordisk INC | $370.20 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $264.57 | 2019-2025 | |
| Daiichi Sankyo INC. | $216.03 | 2019-2024 | Injectafer |
| Lilly USA, LLC | $177.25 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $142.92 | 2019-2021 | |
| Glaxosmithkline, LLC. | $133.83 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $128.39 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.33 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $59.77 | 2023-2024 | Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $52.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.07 | 2019-2020 | |
| Astellas Pharma US INC | $49.92 | 2024-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $44.38 | 2021-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $41.38 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.97 | 2023 | |
| Janssen Pharmaceuticals, INC | $40.49 | 2019-2022 | |
| Exact Sciences Corporation | $31.54 | 2023-2024 | Cologuard Collection Kit |
| Philips North America LLC | $30.22 | 2019-2021 | |
| Shire North American Group INC | $24.84 | 2019 | |
| Idorsia Pharmaceuticals US INC | $20.83 | 2023 | Quviviq |
| Eisai INC. | $19.65 | 2020 | |
| Alexion Pharmaceuticals, INC. | $18.68 | 2021 | |
| Sanofi Pasteur INC. | $17.92 | 2019 | |
| Allergan, INC. | $17.33 | 2020 | |
| Hologic Sales and Service, LLC | $15.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.76 | 2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2019 | |
| Smith+Nephew, INC. | $13.24 | 2019 | |
| Dynavax Technologies Corporation | $5.98 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Walheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.